Published in Biotech Business Week, December 20th, 2004
NIR Diagnostics continues to focus on achieving U.S. Food and Drug Administration (FDA) approval for the HemoNIR device and further validation of the near-infrared platform.
During the quarter, Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, commercially launched the VITROS 5,1 FS Chemistry System. In 2000, Ortho-Clinical Diagnostics, Inc., licensed from NIR Diagnostics patented technology to use light to screen blood samples entering the VITROS 5,1 FS for hemolysis, bilirubin and turbidity.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.